Secondary Logo

Share this article on:

Simonyi G.
Journal of Hypertension: September 2016
doi: 10.1097/01.hjh.0000492148.24335.31
POSTERS’ SESSION PS26: THERAPEUTICS AND CLINICAL TRIALS: PDF Only

Objective:

Monitoring the effectiveness and safety of the fixed dose combination of ramipril/amlodipine therapy in patients with metabolic syndrome suffering from mild or moderate hypertension despite current antihypertensive treatment.

Design and method:

Open, prospective, phase IV clinical observational study, which involved known metabolic syndrome patients (age over 18 years) with mild or moderate hypertension. Ramipril/amlodipine fixed dose combination (5/5, 5/10, 10/5 or, 10/10 mg) were administered or titrated in 3 visits, during the 6 months of trial period. The doses of the fixed combination drugs were determined individually during the visits by physicians involved in the study. The target blood pressure value was <140/90 mmHg (<140/85 mmHg in diabetic subgroup).

Results:

63% of total patient (9,052) has fulfilled the protocol during the six months of trial (5,707 patients). The age of patients was 61.3 ± 11.97 (mean ± SD) years, 2.736 (47.9%) men and 2,971 (52.1%) women. 74.0% of total metabolic patients has reached target blood pressure at the end of 6th month (primary end point). The blood pressure has decreased significantly from 158.7 ± 8.97/91.9 ± 7.30 mmHg (1. visit) to 131.6 ± 7.73/79.8 ± 12.20 (3. visit) (p < 0.0001). Patients with hypertension in metabolic syndrome have tolerated well the various fixed combination of ramipril/amlodipine.

JOURNAL/jhype/04.02/00004872-201609002-00823/figure1-823/v/2017-07-26T042813Z/r/image-tiff

Conclusions:

Introducing ramipril/amlodipine fixed dose combination has a benefitial effect on reaching blood pressure in high risk patietens with metabolic syndrome.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.